MedCity News

JANUARY 24, 2025

Ascentage Pharmas U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers. Takeda holds an exclusive option to develop and commercialize one of those drugs in most of the world. The post Ascentage Has First U.S.

Pharma 238

Pharma Leads Biopharma 238

MedCity News

NOVEMBER 14, 2023

Theseus Pharmaceuticals discontinued its former lead program in July following the report of dose-limiting toxicities in two patients. Though Theseus has other assets in its pipeline, it has decided to explore strategic alternatives with the goal of “maximizing shareholder value.”

Leads 290

Leads Pharma Pharmaceutical Patients 290

MedCity News

AUGUST 4, 2022

billion acquisition of Array Biopharma in 2019. Pfizer is stopping work on a drug for a rare heart disease after an interim look at Phase 3 data indicated that the study was unlikely to succeed. The small molecule came to Pfizer’s drug pipeline as part of the $11.4

Biopharma 312

Biopharma Leads Pharma 312

MedCity News

OCTOBER 20, 2024

Pharmaceutical and biotech companies are using generative AI to predict drug-target interactions, optimize lead compounds, and generate novel molecular structures. The post How Generative AI Will Find a Place in the Pharma Industry Now and in the Years to Come appeared first on MedCity News.

Pharma 331

Pharma Leads Pharmaceutical Biopharma 331

Fierce Pharma

FEBRUARY 21, 2024

In a year that started with more than two-thirds of biopharma companies posting | While Novo Nordisk and Eli Lilly continued to be the biopharma industry growth leaders in the fourth quarter of 2023, many other drugmakers also delivered big gains, including Daiichi Sankyo, Amgen, Teva, GSK and Novartis.

Leads 251

Leads Biopharma Sales 251

MedCity News

APRIL 30, 2024

Morgan Leads $100M Financing for Startup’s R&D of Covalent Biologic Drugs for Cancer appeared first on MedCity News. With cancer as its initial focus, the startup contends its approach could offer safety and efficacy advantages compared to currently available targeted therapies. The post J.P.

Leads 321

Leads Safety Biopharma Pharma 321

MedCity News

APRIL 10, 2024

The lead indication for the Alpine drug, povetacicept, is the chronic kidney disease IgA nephropathy. The post Vertex Pharma Bolsters Immunology Profile With $4.9B Vertex Pharmaceuticals gains a Phase 3-ready Alpine Immune Sciences drug with potential applications in a wide range of immunological disorders.

Pharma 304

Pharma Pharmaceutical Leads Biopharma 304

Fierce Pharma

DECEMBER 2, 2024

s appointment last month to lead the U.S. Department of Health and Human Services immediately sent waves of speculation swirling throughout the biopharma industry. | Kennedy Jr.’s The former FDA Commissioner pointed to the threat of measles if vaccination rates were to decline by 5%.

Biopharma 67

Biopharma FDA Leads 67

MedCity News

MAY 6, 2024

Novo-Catalent Deal, Leading to Another Delay appeared first on MedCity News. Just weeks after Novo decided to resubmit its application to the FTC, the agency is seeking more information about the deal. This move has triggered a second 30-day delay in the antitrust review process. The post FTC Seeks More Information on the $16.5B

Leads 306

Leads Management Biopharma Pharma 306

Fierce Pharma

JANUARY 3, 2024

Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk and Eli Lilly—overwhelming the market wi | Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk (..)

Sales 259

Sales Biopharma Leads Marketing 259

Fierce Pharma

AUGUST 22, 2024

Once again, fueled by booming sales of their GLP-1 products, Eli Lilly and Novo Nordisk were the top performers in the biopharma industry in the second quarter. |

Sales 219

Sales Leads Biopharma 219

MedCity News

MARCH 25, 2024

AbbVie is acquiring Landos Biopharma, whose lead drug is a small molecule that takes a novel approach to treating ulcerative colitis. Preliminary proof-of-concept data from a Phase 2 study are expected later this year.

Biopharma 317

Biopharma Leads Pharma 317

MedCity News

NOVEMBER 27, 2022

The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs. FogPharma is preclinical, but not for long.

Leads 299

Leads Biopharma Pharma 299

MedCity News

DECEMBER 9, 2024

The data, presented Monday during the annual meeting of the American Society of Hematology, are part of a submission now under FDA review that could lead to Blenreps return to the market. The post GSK Multiple Myeloma Drugs DREAMM Comeback Continues With Phase 3 Data at ASH appeared first on MedCity News.

FDA 290

FDA Leads Marketing Patients 290

MedCity News

DECEMBER 5, 2023

Replimune’s lead therapeutic candidate did not meet the two main goals of a study intended to support an FDA submission in cutaneous squamous cell carcinoma. But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer.

Leads 299

Leads FDA Biopharma Pharma 299

MedCity News

JANUARY 19, 2023

Sun Pharmaceuticals is acquiring Concert Pharmaceuticals, a biotech whose lead program has positive data from two late-stage clinical trials in alopecia areata. The deal gives Sun Pharma a drug candidate that could match up against hair loss drugs from two big pharmaceutical companies.

Pharma 278

Pharma Pharmaceutical Leads Biopharma 278

MedCity News

JANUARY 24, 2023

Clinical trial setbacks and financial challenges have led Finch Therapeutics to stop a Phase 3 study for its lead microbiome program, a potential treatment for recurrent C. diff infection. As Finch seeks buyers for its remaining assets, the biotech is laying off most of its staff in a corporate restructuring.

Leads 245

Leads Biopharma Pharma 245

Fierce Pharma

JUNE 7, 2023

Merck has taken the lead, filing a lawsuit seeking to overturn drug pricing measures in the Inflation Reduction Act (IRA). Now, emboldened by the New Jersey drugmaker, other biopharma CEOs are making their concerns known. Merck has filed a lawsuit seeking to overturn drug-pricing measures in the Inflation Reduction Act (IRA).

Biopharma 299

Biopharma Leads 299

MedCity News

MAY 2, 2024

Mariana Oncology brings Novartis a lead radiopharmaceutical program in development for small cell lung cancer. The deal is the latest in a string of big pharma M&A moves in the red-hot radiopharmaceuticals space.

Pharma 321

Pharma Leads Biopharma 321

MedCity News

JANUARY 28, 2025

Lead programs for Huntingtons disease and a rare inherited form epilepsy are on track to enter the clinic this year. The structure of Atalanta Therapeutics RNA interference drugs enables them to distribute broadly and deeply into brain tissue.

Distribution 240

Distribution Leads Biopharma Pharma 240

MedCity News

FEBRUARY 26, 2025

Eikon Therapeutics lead drug candidate is designed to activate toll-like receptors 7 and 8, sparking an immune response that fights cancer. Beyond this TLR7/8 agonist, the biotech is also developing PARP inhibitors that could have advantages over cancer drugs currently available from this class.

Leads 253

Leads Biopharma Pharma 253

MedCity News

SEPTEMBER 12, 2023

The startup’s lead program, an antibody from Astellas Pharma, is a potential treatment for anti-NMDA receptor encephalitis (ANRE), a rare autoimmune inflammatory disorder. Avalon BioVentures unveiled new portfolio company Arialys Therapeutics.

Pharma 311

Pharma Leads Biopharma 311

MedCity News

MARCH 4, 2024

Akero Therapeutics’ preliminary Phase 2b data show that treatment with its MASH drug, efruxifermin, continued to distance itself from a placebo measured at nearly two years of treatment. The latest Akero data build on six-month results reported in 2022.

Leads 312

Leads Biopharma Pharma 312

MedCity News

MAY 18, 2023

The company’s lead product candidate is in mid-stage development for wet age-related macular degeneration and non-proliferative diabetic retinopathy. By selling U.S. rights to Yutiq, EyePoint Pharmaceuticals gets $75 million cash to support its drug pipeline.

Pharma 298

Pharma Pharmaceutical Leads Biopharma 298

MedCity News

JUNE 30, 2024

AbbVie has acquired Celsius Therapeutics, a startup whose lead program is in early clinical development for inflammatory bowel disease. It’s the latest in a series of AbbVie business deals that broaden the pharma company’s scope in the gastrointestinal condition.

Pharma 287

Pharma Leads Biopharma 287

MedCity News

FEBRUARY 12, 2024

FDA approval of Takeda Pharmaceutical drug Eohilia introduces a new therapeutic option for patients with eosinophilic esophagitis, inflammation of the esophagus that causes swallowing difficulty. It will compete against Dupixent, a Sanofi and Regeneron Pharmaceuticals drug already approved for this disorder.

FDA 299

FDA Leads Pharmaceutical Patients 299

MedCity News

JULY 27, 2022

ObsEva’s uterine fibroids drug linzagolix has hit a snag at the FDA, portending a likely delayed regulatory decision. Rather than stick it out and see if its small molecule can match up against commercialized products from AbbVie and Myovant, ObsEva plans to give up rights to the drug as part of a corporate restructuring.

FDA 312

FDA Leads Biopharma Pharma 312

MedCity News

SEPTEMBER 20, 2022

Rocket Pharmaceuticals is acquiring Renovacor, a gene therapies developer whose lead program addresses a particular genetic mutation that leads to a type of heart failure. The all-stock deal gives Rocket the opportunity to expand its reach in genetically driven cardiac diseases.

Pharma 245

Pharma Leads Pharmaceutical Biopharma 245

MedCity News

MARCH 7, 2023

BioMarin Pharmaceutical’s submission of additional data for patients treated with its hemophilia A gene therapy, Roctavian, mean that the FDA will push out a regulatory decision to early summer. But it could be worth the wait as analysts anticipate FDA approval and project Roctavian becoming one of BioMarin’s biggest products.

FDA 278

FDA Leads Pharmaceutical Patients 278

MedCity News

APRIL 24, 2023

A clinical trial for a Foghorn Therapeutics cancer drug is under a partial FDA hold after a patient in the early-stage study developed a cardiovascular complication. It’s the biotech’s second partial hold in the past year.

FDA 276

FDA Leads Patients Biopharma 276

MedCity News

OCTOBER 26, 2022

Realizing the value of cloud, life sciences companies and leading pharma organizations across the world’s R&D teams are increasing operations to collaborate and drive clinical trials.

Pharma 279

Pharma Leads Biopharma 279

MedCity News

MARCH 2, 2023

MorphoSys’s emphasis on its clinical-stage cancer programs puts the spotlight on a myelofibrosis drug candidate from its 2021 acquisition of Constellation Pharmaceuticals. That small molecule could compete against drug candidates from GSK and Merck.

Leads 277

Leads Marketing Pharmaceutical Biopharma 277

MedCity News

JULY 18, 2023

Novartis’s acquisition of DTx Pharma brings a lead program for a rare disease with no FDA-approved therapies. But the deal could also help the pharma giant bring new RNA therapies to new places in the body, a top Novartis executive explained.

Pharma 246

Pharma FDA Leads Biopharma 246

MedCity News

FEBRUARY 13, 2025

The biotechs lead drug candidate is in Phase 3 testing in Prader-Willi syndrome, a genetic disorder that causes persistent hunger leading to overeating. GLP-1 drugs dominate the obesity market, but Aardvark Therapeutics aims to curb appetite by going after a different target: TAS2 receptors in the gut.

Leads 191

Leads Marketing Biopharma Pharma 191

MedCity News

FEBRUARY 13, 2023

G1 Therapeutics said its drug met the main goal of a Phase 3 study in colorectal cancer, but the preliminary results also show measures of survival are better in the placebo arm. The company is stopping the colorectal cancer study.

Leads 264

Leads Biopharma Pharma 264

MedCity News

MAY 29, 2023

Ray Therapeutics’ gene therapy is independent of the causative genes driving inherited vision disorders, which CEO Paul Bresge says is important for reaching a broad patient population. Rare disease retinitis pigmentosa is the first disease target, but the startup also plans to test its approach in more prevalent eye disorders.

Leads 279

Leads Patients Biopharma Pharma 279

MedCity News

JULY 11, 2023

Septerna Therapeutics’ Series B financing will support plans to reach the clinic with a pill for a rare disease whose only approved therapy is a Takeda Pharmaceutical drug that’s leaving the market. Potential rival therapies are all injectables.

Leads 214

Leads Pharmaceutical Marketing Biopharma 214